ULTRAGREEN AI USD (ULG.SI) saw its stock price soar by 3.50% during intraday trading on Tuesday.
The surge follows analysis from DBS Group Research suggesting the company is unlikely to be negatively impacted by the Trump administration's decision to impose a 100% tariff on patented pharmaceutical products. The firm's water-soluble, FDA-approved dye used for fluorescence imaging is classified as a generic drug and falls under the current tariff exemption.
Analysts added that demand for the product is expected to remain relatively price-inelastic, and the company should be able to pass on any potential future tariff-related costs to customers. An additional mitigating factor is that UltraGreen.ai's kits for the Americas are packaged in Michigan. DBS maintains its buy rating and a US$2.00 target price for the stock.